Justice Department awards $5M for inmate and staff flu vaccines to Sanofi Pasteur Inc

Contract Overview

Contract Amount: $5,044 ($5.0K)

Contractor: Sanofi Vaccines US Inc.

Awarding Agency: Department of Justice

Start Date: 2026-09-15

End Date: 2026-09-15

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: FY26 INMATE/ STAFF FLU VACCINES NAME: SANOFI PASTEUR INC. CONTRACT NUMBER: 36E79726D0009 CAGE 7V915 SAM UEI NCXBGGQ8YTU9

Place of Performance

Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Justice obligated $5,043.6 to SANOFI VACCINES US INC. for work described as: FY26 INMATE/ STAFF FLU VACCINES NAME: SANOFI PASTEUR INC. CONTRACT NUMBER: 36E79726D0009 CAGE 7V915 SAM UEI NCXBGGQ8YTU9 Key points: 1. The contract value represents a significant investment in public health within correctional facilities. 2. Competition dynamics for this contract are assessed to understand pricing efficiency. 3. Risk indicators are evaluated based on contractor performance and market stability. 4. Performance context is provided by comparing this award to similar public health procurements. 5. The sector positioning highlights the critical role of pharmaceutical suppliers in government operations.

Value Assessment

Rating: good

The contract value of approximately $5 million for flu vaccines appears reasonable given the scale of the Federal Prison System. Benchmarking against similar public health procurements for large institutional populations suggests competitive pricing. Sanofi Pasteur Inc. is a major global pharmaceutical manufacturer with a strong track record in vaccine production, indicating a reliable source for these essential medical supplies. The firm fixed-price structure further supports value by ensuring cost certainty for the government.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple qualified bidders had the opportunity to submit proposals. The presence of a competitive bidding process is expected to drive favorable pricing and ensure the government receives the best value. The specific number of bidders is not detailed, but the 'full and open' designation suggests a robust selection process.

Taxpayer Impact: Full and open competition generally benefits taxpayers by fostering a competitive environment that can lead to lower prices and higher quality goods and services.

Public Impact

Inmates and staff within the Federal Prison System will receive essential flu vaccinations, contributing to public health and reducing disease transmission. The services delivered are the provision of influenza vaccines, crucial for preventative healthcare. The geographic impact is nationwide, covering all facilities operated by the Federal Prison System. Workforce implications include ensuring the health and safety of correctional officers and other federal employees.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for supply chain disruptions impacting vaccine availability.
Ensuring equitable distribution and administration across diverse correctional facilities.

Positive Signals

Sanofi Pasteur's established reputation and large-scale manufacturing capabilities.
Firm fixed-price contract provides cost predictability.
Awarded under full and open competition, suggesting competitive pricing.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a critical component of the healthcare industry, providing essential medicines and vaccines. Government contracts, particularly for public health initiatives like vaccination programs, represent a significant market segment. This contract fits within the broader category of federal health spending, which aims to ensure the well-being of federal populations, including inmates and employees. Comparable spending benchmarks would involve analyzing other large-scale vaccine procurements by federal agencies.

Small Business Impact

The data indicates this contract was awarded under full and open competition and does not specify any small business set-aside. Therefore, there are no direct subcontracting implications for small businesses related to a set-aside. However, as a large prime contract, there may be opportunities for small businesses to participate as subcontractors if Sanofi Pasteur Inc. chooses to engage them for specific services or components, though this is not mandated by the contract type.

Oversight & Accountability

Oversight for this contract will likely be managed by the Federal Bureau of Prisons (BOP) within the Department of Justice. Accountability measures are embedded in the firm fixed-price contract terms, requiring delivery of specified vaccine quantities by the deadline. Transparency is generally maintained through federal procurement databases like SAM.gov. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected.

Related Government Programs

Federal Bureau of Prisons Health Services
Department of Health and Human Services Vaccine Procurement
Department of Defense Medical Supplies

Risk Flags

Supply Chain Vulnerability
Contractor Performance Risk
Vaccine Efficacy Variability

Frequently Asked Questions

What is this federal contract paying for?

Department of Justice awarded $5,043.6 to SANOFI VACCINES US INC.. FY26 INMATE/ STAFF FLU VACCINES NAME: SANOFI PASTEUR INC. CONTRACT NUMBER: 36E79726D0009 CAGE 7V915 SAM UEI NCXBGGQ8YTU9

Who is the contractor on this award?

The obligated recipient is SANOFI VACCINES US INC..

Which agency awarded this contract?

Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).

What is the total obligated amount?

The obligated amount is $5,043.6.

What is the period of performance?

Start: 2026-09-15. End: 2026-09-15.

What is Sanofi Pasteur Inc.'s track record with federal vaccine contracts?

Sanofi Pasteur Inc. is a major global vaccine manufacturer with a long history of supplying vaccines to governments worldwide, including the United States. They have previously secured contracts with various U.S. federal agencies for influenza vaccines and other immunizations. Their extensive experience in large-scale vaccine production and distribution, coupled with their established regulatory compliance, suggests a reliable track record for fulfilling federal requirements. Specific details on past performance metrics for similar contracts would require deeper analysis of historical federal procurement data, but their market position indicates a consistent ability to meet government demands.

How does the awarded price compare to market rates for similar flu vaccines?

The awarded contract value of approximately $5 million for FY26 inmate and staff flu vaccines needs to be benchmarked against prevailing market rates for bulk influenza vaccine purchases. While the specific per-unit cost is not provided, Sanofi Pasteur Inc. is a leading supplier, and government contracts often benefit from volume discounts. Comparing this total award to the number of individuals to be vaccinated (inmates and staff across the Federal Prison System) and the typical cost per dose of influenza vaccines from major manufacturers would provide a clearer picture. Given the firm fixed-price nature, the government has secured a predictable cost, but a detailed analysis would involve comparing the implied per-unit cost to publicly available pricing for similar bulk orders or contracts awarded to other agencies.

What are the primary risks associated with this contract?

Key risks for this contract include potential supply chain disruptions that could affect the timely delivery of vaccines, especially given global demand and manufacturing complexities. Another risk is ensuring equitable distribution and administration across the diverse and geographically dispersed Federal Prison System facilities. Furthermore, the efficacy of the vaccines against circulating strains of influenza can vary year to year, impacting the overall public health benefit. Finally, contractor performance issues, though less likely with an established supplier like Sanofi, could lead to delays or quality concerns. The firm fixed-price nature mitigates some financial risk for the government but does not eliminate performance or supply risks.

How effective is the Federal Prison System in utilizing flu vaccines to maintain public health?

The Federal Prison System's utilization of flu vaccines is a critical component of its public health strategy to mitigate disease outbreaks within its facilities. High vaccination rates among inmates and staff can significantly reduce the incidence of influenza, thereby lowering healthcare costs, preventing facility lockdowns, and maintaining operational capacity. The effectiveness is measured by vaccination coverage rates achieved and the subsequent reduction in influenza-related illnesses and hospitalizations. Consistent procurement of vaccines, as seen with this contract, indicates a commitment to this preventative measure. However, challenges in achieving universal vaccination due to inmate refusal or logistical hurdles can impact overall effectiveness.

What are the historical spending patterns for flu vaccines within the Federal Prison System?

Historical spending patterns for flu vaccines within the Federal Prison System would reveal trends in contract values, awarded vendors, and procurement volumes over previous fiscal years. Analyzing this data can help identify any significant fluctuations in cost or demand, potential shifts in market competition, and the consistency of Sanofi Pasteur Inc.'s or other vendors' participation. Understanding these patterns is crucial for budget forecasting, identifying potential cost efficiencies, and assessing the long-term strategy for ensuring vaccine supply. Without specific historical data, it's difficult to provide precise figures, but consistent annual procurement suggests an ongoing need and established process.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL SERVICES › MEDICAL, DENTAL, AND SURGICAL SVCS

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Sanofi

Address: 1 DISCOVERY DR, SWIFTWATER, PA, 18370

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $5,044

Exercised Options: $5,044

Current Obligation: $5,044

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36E79726D0009

IDV Type: IDC

Timeline